Dear Editor,

The mechanisms involved in chronic myeloid leukemia (CML) progression from the chronic phase (CP) to an accelerated phase (AP) or blast crisis (BC) remain largely undetermined, but generally involve additional molecular changes besides the Philadelphia chromosome \[[@B1]\]. Evidence suggests that secondary *BCR* (breakpoint cluster region)-*ABL1* (Abelson murine leukemia viral oncogene homolog 1)-dependent/independent genetic events play a critical role in blast transformation \[[@B2]\]. Besides *BCR-ABL1* point mutations, deletions and/or rearrangements of other cancer-related genes have been associated with CML-BC \[[@B2]\]. Recent studies have demonstrated that aberrant activation-induced cytidine deaminase (*AID*) expression promotes genetic instability, eventually leading to progression and drug resistance in CML \[[@B3]\].

We report a patient with a rare chromosomal translocation 46,XY,t(5;12)(p13;p13) that disrupts *AID* and causes a concomitant deletion of the tumor suppressor gene *BCL7A* (B-cell CLL/lymphoma 7A). This report presents evidence of a mechanism underlying CML progression and tyrosine kinase inhibitor (TKI) resistance occurring through an interaction between *AID* expression and *BCL7A* loss in a *BCR-ABL1* kinase domain mutation-independent manner.

A 57-yr-old man presented in December 2010 with generalized weakness and chest pain. Bone marrow (BM) demonstrated nearly packed marrow owing to myeloid and megakaryocyte hyperplasia (blasts \[0.4%\]). Written informed consent for genetic analysis was obtained from the patient according to the ethical guidance of the institutional review board. The patient exhibited the b3a2 type *BCR-ABL1* fusion transcript, and cytogenetic analysis revealed a normal karyotype. The patient was diagnosed as having CML-CP and treated with imatinib ([Table 1](#T1){ref-type="table"}).

Sixteen months following diagnosis, treatment was replaced by dasatinib since *BCR-ABL1* transcripts had not declined. Simultaneously, one of 25 metaphase cells exhibited an abnormal karyotype of 46,XY,t(5;12)(p13;p13) ([Fig. 1A](#F1){ref-type="fig"}). FISH analysis using a *TEL/AML1* translocation probe presented a normal result; therefore, another gene on chromosome 12p13 was suspected to be involved. Subsequent FISH analysis revealed a break in the *AID* signal on one allele in 12.2% of interphase cells using a custom-labeled probe (Empire Genomics LLC, Buffalo, NY, USA) ([Fig. 1B](#F1){ref-type="fig"}) compared with 0.2% of normal control cells. Quantitative analysis showed that *AID* RNA expression increased, whereas normal cells showed no *AID* expression.

Chromosomal microarray using a CytoScan 750K Array (Affymetrix Inc., Santa Clara, CA, USA) revealed a 1.9-Mb deletion mostly containing *BCL7A* on chromosome 12q24.31 ([Fig. 1C](#F1){ref-type="fig"}).

After 28 months, the patient progressed to CML-AP, and the CBC showed leukocyte counts of 116.8×10^9^/L and 13% blasts. *BCR-ABL1* kinase domain sequencing revealed no mutation. Conversely, chromosomal abnormality of t(5;12)(p13;p13) exhibited clonal expansion. Thus, the patient was returned to imatinib therapy and subsequently demonstrated a complete hematologic response; however, *AID* breakage and *BCR-ABL1* transcript levels remained detectable.

After 37 months, the patient presented again with CML-AP, with 13.5% blasts in peripheral blood, and karyotyping showed 46,XY,t(5;12)(p13;p13)\[6\]/46,XY\[14\]. The patient received allogeneic stem cell transplantation and achieved complete donor hematopoietic chimerism.

The *AID* gene, located on chromosome 12p13, is associated with genomic instability and ensuing oncogenesis in various human malignancies including CML, AML, and ALL \[[@B3][@B4][@B5]\]. *AID* has several non-immunoglobulin targets, including *PAX5* and *BCL7A* \[[@B3][@B6]\]; *PAX5* can induce TKI resistance and CML progression via *AID* upregulation \[[@B3]\].

Recently, it was shown that *AID* activation can induce mutations and translocations at the *BCL7A* locus \[[@B6]\]. *BCL7A* belongs to the BCL7 family, which includes *BCL7B* and *BCL7C*, and is a known pro-apoptotic tumor suppressor in B-cell oncogenesis. Specifically, BCL7B suppresses β-catenin expression, causing Wnt signaling inhibition \[[@B7]\]. Importantly, β-catenin deregulation in Wnt signaling is associated with genomic instability that can induce oncogenic translocations in T-cell lymphoma and AML \[[@B5][@B8]\]. In CML, β-catenin activation is observed in the AP or BC, and is believed to promote leukemic stem cell generation that facilitates disease progression \[[@B9]\].

We suggest a novel pathway for disease progression and drug resistance in CML via *AID* expression and the concomitant loss of *BCL7A*. Our case supports the hypothesis that *BCL7A* deletion induces abnormal Wnt/β-catenin signaling, enhancing the potential for a chromosomal aberration and its persistence in our patient \[[@B5][@B10]\]. Loss of the tumor suppressor *BCL7A* may cooperate with *AID* activity in disease progression by causing aberrant cell cycle regulation \[[@B1]\]. Moreover, *AID*-induced DNA damage checkpoint activation causes initiation of tumor suppressor genes involved in DNA repair or cell cycle control \[[@B1]\]. A previous study showed that decreased tumor suppressor gene expression can cause *AID*-induced translocation, eventually leading to cancer \[[@B10]\].

In conclusion, our report identifies that *AID*, in combination with *BCL7A*, likely confers TKI resistance in a *BCR-ABL1* kinase domain mutation-independent manner and may be a putative functional target in CML therapy.
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![Genetic analysis of CML-AP BM samples. (A) Translocation site in G-banded karyotyping of the 46,XY,t(5;12)(p13;p13) (arrows). (B) Interphase FISH confirming three signals of the *AID* probe (red), resulting from *AID* rearrangement at the 12p13 locus. (4,6-diamidino-2-phenylindole stain, ×1,000). (C) Chromosomal microarray revealing copy number loss in the chromosome 12q24.31 region (arrow). Blue dots with a log2 transformed value of -1 represent a 1:2 copy number ratio to the reference genomic DNA, indicating a heterozygous deletion. The expansion view of the 12q24 region reveals a 1.9-Mb heterozygous interstitial deletion in chromosome 12 (121,949,449-123,968,599; hg19) that includes the *BCL7A* gene.\
Abbreviations: AP, accelerated phase; BM, bone marrow; *AID*, activation-induced cytidine deaminase; *BCL7A*, B-cell CLL/lymphoma 7A.](alm-37-177-g001){#F1}

###### The clinical course of the patient

![](alm-37-177-i001)

  Time (months after diagnosis)                                    0          3      12     16                                              23    28                                              29         32      37                                              38                      46
  ---------------------------------------------------------------- ---------- ------ ------ ----------------------------------------------- ----- ----------------------------------------------- ---------- ------- ----------------------------------------------- ----------------------- --------------------------
  Diagnosis                                                        CML-CP     CHR    \-     CHR                                             \-    CML-AP                                          CHR        \-      CML-AP                                          Mixed donor chimerism   Complete donor chimerism
  Karyotype                                                        \-         \-     \-     46,XY,t(5;12) (p13;p13) \[[@B1]\]/46,XY\[24\]   \-    46,XY,t(5;12) (p13;p13) \[[@B5]\]/46,XY\[15\]   \-         \-      46,XY,t(5;12) (p13;p13) \[[@B6]\]/46,XY\[14\]   \-                      \-
  *BCR-ABL1* transcript (relative ratio of *BCR-ABL1* to *ABL1*)   0.00352    0.08   0.03   0.03                                            0.3   \-                                              0.09^\*^   0.089   \-                                              0.000223                Negative
  Interphase FISH (% of *AID* rearrangement)                       \-         \-     \-     12.2                                            \-    \-                                              9.5        \-      9.8                                             \-                      \-
  *AID* mRNA expression (relative ratio of *AID* to *ACTB*)        \-         \-     \-     3.53                                            \-    \-                                              3.23       \-      5.32                                            \-                      \-
  *BCL7A* copy number changes                                      Normal     \-     \-     Deletion                                        \-    \-                                              \-         \-      \-                                              \-                      \-
  Treatment                                                        Imatinib   \-     \-     Dasatinib                                       \-    Nilotinib                                       Imatinib   \-      Allogeneic PBSCT                                \-                      \-

^\*^The real-time PCR method changed from LightCycler t(9;22) Quantification (Roche Molecular Systems, Branchburg, NJ, USA) to Real-Q *BCR-ABL1* Quantification (BioSewoom, Seoul, Korea) at the six month follow-up.

Abbreviations: BM, bone marrow; CHR, complete hematologic response; AP, accelerated phase; CP, chronic phase; AID, activation-induced cytidine deaminase; PBSCT, peripheral blood stem cell transplantation.
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